Anti-angiogenic and anti-HER therapy

Giampietro Gasparini; Roberta Sarmiento; Raffaele Longo

doi:10.1016/j.biopha.2006.06.001

Anti-angiogenic and anti-HER therapy

Giampietro Gasparini, Roberta Sarmiento, Raffaele Longo

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article › peer-review

Abstract

The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called "target oriented therapies".

Original language	English
Pages (from-to)	263-265
Number of pages	3
Journal	Biomedicine and Pharmacotherapy
Volume	60
Issue number	6
DOIs	https://doi.org/10.1016/j.biopha.2006.06.001
Publication status	Published - Jul 2006

Keywords

Angiogenesis
Molecular-target therapy
Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.biopha.2006.06.001

Fingerprint Dive into the research topics of 'Anti-angiogenic and anti-HER therapy'. Together they form a unique fingerprint.

Cite this

@article{084c236e33ae40d9a6f9cd1fb1f395cf,

title = "Anti-angiogenic and anti-HER therapy",

abstract = "The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called {"}target oriented therapies{"}.",

keywords = "Angiogenesis, Molecular-target therapy, Vascular endothelial growth factor (VEGF)",

author = "Giampietro Gasparini and Roberta Sarmiento and Raffaele Longo",

year = "2006",

month = jul,

doi = "10.1016/j.biopha.2006.06.001",

language = "English",

volume = "60",

pages = "263--265",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson SAS",

number = "6",

}

TY - JOUR

T1 - Anti-angiogenic and anti-HER therapy

AU - Gasparini, Giampietro

AU - Sarmiento, Roberta

AU - Longo, Raffaele

PY - 2006/7

Y1 - 2006/7

N2 - The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called "target oriented therapies".

AB - The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called "target oriented therapies".

KW - Angiogenesis

KW - Molecular-target therapy

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=33747097462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747097462&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2006.06.001

DO - 10.1016/j.biopha.2006.06.001

M3 - Article

C2 - 16815667

AN - SCOPUS:33747097462

VL - 60

SP - 263

EP - 265

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6

ER -